

REMARKS

In response to the lack of unity determination imposed in the outstanding Official Action of September 9, 2005, applicants hereby provisionally elect Group V, with traverse.

As to the election of species requirement, applicants provisionally elect compound 13 (AL245) and the utilization of the complex in radioimmunotherapy.

The grounds for traverse are that an examination of all their claims in their full scope fails to place an undue burden on the Patent Office. As the Examiner is aware, a search and examination of the application has already been completed by the Patent Office. Indeed, as the Examiner is aware, an Office Action has already been entered in the present application.


While the Office Action acted on claims 1-18 (which have been canceled), applicants note that the new claims (19-38) are directed to the subject matter of claims 1-18. Claims 19-38 were added so that the subject matter of claims 1-18 could be drafted in a manner to reflect preferred United States patent practice.

As a search and examination of the claimed subject matter has already been completed, applicants respectfully submit that an examination of all their claims in their full scope fails to place a burden on the Patent Office. As a result, applicants respectfully request that the lack of unity determination be withdrawn.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON


Philip A. DuBois, Reg. No. 50,696
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573

PD/mjr